Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 13/20 | 0.74 |
| ▸ | TAS1R1 | Q7RTX1 | 12/20 | 0.74 |
| ▸ | TAS1R2 | Q8TE23 | 10/20 | 0.74 |
| ▸ | GRM5 | P41594 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751349 | 0.85 | TAS1R3 (1.00) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL20662814 | 0.84 | TAS1R3 (0.85) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL1667825 | 0.83 | RAB9A (0.73) | GRM5NPC1LMNAGAARAB9A | |
| SCHEMBL14198236 | 0.82 | TAS1R3 (0.74) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL4177737 | 0.82 | TAS1R3 (0.74) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL11241115 | 0.82 | RAB9A (0.75) | GRM5NPC1LMNAGAARAB9A | |
| SCHEMBL3355320 | 0.81 | TAS1R3 (0.67) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL20713198 | 0.81 | TAS1R3 (0.70) | TAS1R3TAS1R1TAS1R2GRM5MEN1 | |
| SCHEMBL2468483 | 0.80 | NPC1 (0.71) | GRM5NPC1LMNAGAARAB9A | |
| SCHEMBL517318 | 0.80 | TAS1R3 (0.72) | TAS1R3TAS1R1TAS1R2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090047379-A1 | Benzamide Compounds Useful as High Potency Sweet Taste Enhancers | DEWIS MARK L | 2009-02-19 | — | — | US | disclosed |
| US-20090047379-A1 | Benzamide Compounds Useful as High Potency Sweet Taste Enhancers | DEWIS MARK L | 2009-02-19 | — | — | US | disclosed |
| US-20090047379-A1 | Benzamide Compounds Useful as High Potency Sweet Taste Enhancers | DEWIS MARK L | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047379-A1 | Benzamide Compounds Useful as High Potency Sweet Taste Enhancers | TAS2R10, TAS2R50, TAS2R8 | TAS1R3 27/4885TAS1R1 23/4885TAS1R2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.